Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1968 2
1970 1
1971 3
1972 1
1974 1
1975 1
1976 6
1977 9
1979 4
1980 5
1981 2
1982 5
1983 3
1984 8
1985 3
1986 2
1987 3
1988 2
1989 4
1990 10
1991 6
1992 6
1993 6
1994 6
1995 4
1996 7
1997 7
1998 6
1999 6
2000 8
2001 8
2002 19
2003 13
2004 24
2005 24
2006 21
2007 25
2008 25
2009 25
2010 35
2011 42
2012 44
2013 32
2014 57
2015 62
2016 70
2017 89
2018 88
2019 117
2020 153
2021 185
2022 187
2023 202
2024 75

Text availability

Article attribute

Article type

Publication date

Search Results

1,567 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Kanetaki
Page 1
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Cunningham AL, et al. N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800. N Engl J Med. 2016. PMID: 27626517 Free article. Clinical Trial.
Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS: In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received …
Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled …
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ, Choo EJ, Curiac D, Di Paolo E, Dionne M, Eckermann T, Esen M, Ferguson M, Ghesquiere W, Hwang SJ, Avelino-Silva TJ, Kosina P, Liu CS, Markkula J, Moeckesch B, Murta de Oliveira C, Park DW, Pauksens K, Pirrotta P, Plassmann G, Pretswell C, Rombo L, Salaun B, Sanmartin Berglund J, Schenkenberger I, Schwarz T, Shi M, Ukkonen B, Zahaf T, Zerbini C, Schuind A, Cunningham AL; Zoster-049 Study Group. Boutry C, et al. Clin Infect Dis. 2022 Apr 28;74(8):1459-1467. doi: 10.1093/cid/ciab629. Clin Infect Dis. 2022. PMID: 34283213 Free PMC article. Clinical Trial.
BACKGROUND: This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age 50 years in 2 pivotal efficacy trials (ZOE- …
BACKGROUND: This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccina …
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, Louca P, May A, Figueiredo JC, Hu C, Molteni E, Canas L, Österdahl MF, Modat M, Sudre CH, Fox B, Hammers A, Wolf J, Capdevila J, Chan AT, David SP, Steves CJ, Ourselin S, Spector TD. Menni C, et al. Lancet. 2022 Apr 23;399(10335):1618-1624. doi: 10.1016/S0140-6736(22)00327-0. Epub 2022 Apr 7. Lancet. 2022. PMID: 35397851 Free PMC article.
METHODS: In this prospective longitudinal observational study, we collected data from participants who were self-reporting test results and symptoms in the ZOE COVID app (previously known as the COVID Symptoms Study App). ...Our data indicate a shorter period of illness an …
METHODS: In this prospective longitudinal observational study, we collected data from participants who were self-reporting test results and …
Pulp treatment for extensive decay in primary teeth.
Smaïl-Faugeron V, Glenny AM, Courson F, Durieux P, Muller-Bolla M, Fron Chabouis H. Smaïl-Faugeron V, et al. Cochrane Database Syst Rev. 2018 May 31;5(5):CD003220. doi: 10.1002/14651858.CD003220.pub3. Cochrane Database Syst Rev. 2018. PMID: 29852056 Free PMC article. Review.
Similarly inconclusive, there was no clear evidence of a difference in failure between Endoflas and ZOE (outcomes measured at 6 months; two trials, 80 participants). There was low-quality evidence of a difference in failure at 12 months that suggested ZOE paste may …
Similarly inconclusive, there was no clear evidence of a difference in failure between Endoflas and ZOE (outcomes measured at 6 month …
Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster.
Syed YY. Syed YY. Drugs Aging. 2018 Dec;35(12):1031-1040. doi: 10.1007/s40266-018-0603-x. Drugs Aging. 2018. PMID: 30370455 Review.
The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged 50 years. In the pivotal trials in adults aged 50 years (ZOE-50) and 70 years (ZOE-70), …
The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia ( …
Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study.
Bermingham KM, Linenberg I, Hall WL, Kadé K, Franks PW, Davies R, Wolf J, Hadjigeorgiou G, Asnicar F, Segata N, Manson JE, Newson LR, Delahanty LM, Ordovas JM, Chan AT, Spector TD, Valdes AM, Berry SE. Bermingham KM, et al. EBioMedicine. 2022 Nov;85:104303. doi: 10.1016/j.ebiom.2022.104303. Epub 2022 Oct 18. EBioMedicine. 2022. PMID: 36270905 Free PMC article.
INTERPRETATION: Findings from this large scale, in-depth nutrition metabolic study of menopause, support the importance of monitoring risk factors for type-2 diabetes and cardiovascular disease in mid-life to older women to reduce morbidity and mortality associated with oestrogen …
INTERPRETATION: Findings from this large scale, in-depth nutrition metabolic study of menopause, support the importance of monitoring risk f …
A comparison of calcium hydroxide/iodoform paste and zinc oxide eugenol as root filling materials for pulpectomy in primary teeth: A systematic review and meta-analysis.
Najjar RS, Alamoudi NM, El-Housseiny AA, Al Tuwirqi AA, Sabbagh HJ. Najjar RS, et al. Clin Exp Dent Res. 2019 Mar 4;5(3):294-310. doi: 10.1002/cre2.173. eCollection 2019 Jun. Clin Exp Dent Res. 2019. PMID: 31249711 Free PMC article.
Zinc oxide eugenol (ZOE) has traditionally been used as a root filling material in primary teeth pulpectomy. ...It is challenging to select the appropriate filling materials for primary teeth. ZOE or ZOE/iodoform combined with Ca(OH)(2) appears to be the mate …
Zinc oxide eugenol (ZOE) has traditionally been used as a root filling material in primary teeth pulpectomy. ...It is challenging to …
"Monkey-See, Monkey-Do".
Finer ZR, Lopez CR, Naik RD. Finer ZR, et al. Gastroenterology. 2023 Nov;165(5):e5-e9. doi: 10.1053/j.gastro.2023.05.022. Epub 2023 May 26. Gastroenterology. 2023. PMID: 37245589 No abstract available.
Clinical and radiographic evaluation of pulpectomy in primary teeth: a 18-months clinical randomized controlled trial.
Chen X, Liu X, Zhong J. Chen X, et al. Head Face Med. 2017 Oct 27;13(1):12. doi: 10.1186/s13005-017-0145-1. Head Face Med. 2017. PMID: 29073902 Free PMC article. Clinical Trial.
The Aim of this study was to compare the success rates of a mixed primary root canal filling (MPRCF, ingredients: zinc oxide-eugenol [ZOE], iodoform, calcium hydroxide) to those of ZOE and Vitapex in pulpectomised primary molars. ...There was a statistically signifi …
The Aim of this study was to compare the success rates of a mixed primary root canal filling (MPRCF, ingredients: zinc oxide-eugenol [ZOE …
Cavity Bases Revisited.
Arandi NZ, Rabi T. Arandi NZ, et al. Clin Cosmet Investig Dent. 2020 Jul 24;12:305-312. doi: 10.2147/CCIDE.S263414. eCollection 2020. Clin Cosmet Investig Dent. 2020. PMID: 32801924 Free PMC article. Review.
OBJECTIVE: The aim of this paper was to review the current literature on cavity bases while focusing on the role of zinc oxide eugenol (ZOE) and resin-modified glass ionomers (RMGI) as cavity bases. MATERIALS AND METHODS: A thorough literature search between 1970 and 2020 …
OBJECTIVE: The aim of this paper was to review the current literature on cavity bases while focusing on the role of zinc oxide eugenol (Z …
1,567 results